Cybin Inc. (CYBN)
7.16
0.10 (1.42%)
At close: Apr 25, 2025, 11:43 AM
1.42% (1D)
| Bid | 7.01 |
| Market Cap | 150.55M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -103.9M |
| EPS (ttm) | -3.66 |
| PE Ratio (ttm) | -1.96 |
| Forward PE | -1.61 |
| Analyst | Buy |
| Ask | 7.19 |
| Volume | 59,489 |
| Avg. Volume (20D) | 330,694.8 |
| Open | 7.06 |
| Previous Close | 7.06 |
| Day's Range | 7.00 - 7.20 |
| 52-Week Range | 4.81 - 14.44 |
| Beta | 1.09 |
About CYBN
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 13, 2019
Employees 50
Stock Exchange AMEX
Ticker Symbol CYBN
Website https://www.cybin.com
Analyst Forecast
According to 4 analyst ratings, the average rating for CYBN stock is "Buy." The 12-month stock price forecast is $73, which is an increase of 919.55% from the latest price.
Stock Forecasts10 months ago
-9.67%
Shares of psychedelics companies are trading lower...
Unlock content with
Pro Subscription
